Zhang Zhen-zhen, Zhang Xin-zhuang, Li Na, Cao Liang, Ding Gang, Wang Zhen-zhong, Xiao Wei
Zhongguo Zhong Yao Za Zhi. 2015 Mar;40(6):993-8.
The aim of this study was to investigate the anti-inflammatory effect of Guizhi Fuling capsule and its active complex (consistent of 15 active compounds) on LPS-induced RAW264. 7 cells. The effect of Guizhi Fuling capsule and its active complex on cell viability in RAW264. 7 cells were determined by MTT assay. The inhibitory effect of Guizhi Fuling capsule and active complex on the releasing of IL-1β, TNF-α and PGE2 induced by LPS in RAW264. 7 cells was detected by ELISA assay. The expression of IL-1β and mPGES-1 in Guizhi Fuling capsule or active complex treated RAW264. 7 cells was examined by Western blot assay. Guizhi Fuling capsule and active complex showed no significant effect on the cell viability in RAW264. 7 cells at doses range from 12.5 to 400 mg x L(-1). Compared with LPS treated group, Guizhi Fuling capsule and active complex dose dependently reduced the releasing of IL-1β, TNF-α and PGE2 induced by LPS in RAW264. 7 cells. Moreover, the expression of IL-1β and mPGES-1 was decreased after Guizhi Fuling capsule and active complex treatment, which might contribute to the inhibitory effect of Guizhi Fuling capsule in the releasing of IL-1β, TNF-α and PGE2. This study provided the evidence that Guizhi Fuling capsule and active complex remarkably inhibited the releasing of IL-1β, TNF-α and PGE2induced by LPS in RAW264. 7 cells by reducing the expression IL-1β and mPGES-1. This study provided an experimental basis of Guizhi Fuling capsule for the treatment of inflammation and a theoretical basis for the development of effective compounds of Guizhi Fuling capsule.
本研究旨在探讨桂枝茯苓胶囊及其活性复合物(由15种活性成分组成)对脂多糖(LPS)诱导的RAW264.7细胞的抗炎作用。采用MTT法测定桂枝茯苓胶囊及其活性复合物对RAW264.7细胞活力的影响。采用酶联免疫吸附测定(ELISA)法检测桂枝茯苓胶囊及其活性复合物对LPS诱导RAW264.7细胞释放白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)和前列腺素E2(PGE2)的抑制作用。采用蛋白质免疫印迹法检测经桂枝茯苓胶囊或活性复合物处理的RAW264.7细胞中IL-1β和微粒体前列腺素E合酶-1(mPGES-1)的表达。在12.5至400mg·L-1剂量范围内,桂枝茯苓胶囊及其活性复合物对RAW264.7细胞活力无显著影响。与LPS处理组相比,桂枝茯苓胶囊及其活性复合物能剂量依赖性地降低LPS诱导RAW264.7细胞释放IL-1β、TNF-α和PGE2。此外,经桂枝茯苓胶囊和活性复合物处理后,IL-1β和mPGES-1的表达降低,这可能是桂枝茯苓胶囊抑制IL-1β、TNF-α和PGE2释放的原因。本研究证明,桂枝茯苓胶囊及其活性复合物可通过降低IL-1β和mPGES-1的表达,显著抑制LPS诱导RAW264.7细胞释放IL-1β、TNF-α和PGE2。本研究为桂枝茯苓胶囊治疗炎症提供了实验依据,也为桂枝茯苓胶囊有效成分的开发提供了理论依据。